Cargando…
Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
OBJECTIVE: To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). METHODS: Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective stu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225508/ https://www.ncbi.nlm.nih.gov/pubmed/33589732 http://dx.doi.org/10.1038/s41372-021-00963-5 |
_version_ | 1783712106435051520 |
---|---|
author | Pan, Jiarong Zhan, Canyang Yuan, Tianming Chen, Xiangxiang Ni, Yanyan Shen, Ying Chen, Weiwei Wu, Tai Yu, Huimin |
author_facet | Pan, Jiarong Zhan, Canyang Yuan, Tianming Chen, Xiangxiang Ni, Yanyan Shen, Ying Chen, Weiwei Wu, Tai Yu, Huimin |
author_sort | Pan, Jiarong |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). METHODS: Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective study. Patients treated with IVIG and phototherapy were classified as the IVIG group, and those who only received phototherapy were classified as the phototherapy only group. RESULTS: Forty-six patients were classified into the IVIG group and 68 other patients were classified into the phototherapy only group. There was no significant difference in duration of phototherapy, hospitalization periods, needs for exchange transfusion, transfusions, and incidence of bilirubin-induced neurological sequelae between these two groups (P = 0.20, 0.27, 0.65, 0.47, 0.78, respectively). CONCLUSION: It seems unnecessary to expose neonates to IVIG in moderate-to-severe ABO HDN when the available data show no appreciable benefits. |
format | Online Article Text |
id | pubmed-8225508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-82255082021-07-13 Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study Pan, Jiarong Zhan, Canyang Yuan, Tianming Chen, Xiangxiang Ni, Yanyan Shen, Ying Chen, Weiwei Wu, Tai Yu, Huimin J Perinatol Article OBJECTIVE: To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). METHODS: Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective study. Patients treated with IVIG and phototherapy were classified as the IVIG group, and those who only received phototherapy were classified as the phototherapy only group. RESULTS: Forty-six patients were classified into the IVIG group and 68 other patients were classified into the phototherapy only group. There was no significant difference in duration of phototherapy, hospitalization periods, needs for exchange transfusion, transfusions, and incidence of bilirubin-induced neurological sequelae between these two groups (P = 0.20, 0.27, 0.65, 0.47, 0.78, respectively). CONCLUSION: It seems unnecessary to expose neonates to IVIG in moderate-to-severe ABO HDN when the available data show no appreciable benefits. Nature Publishing Group US 2021-02-15 2021 /pmc/articles/PMC8225508/ /pubmed/33589732 http://dx.doi.org/10.1038/s41372-021-00963-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pan, Jiarong Zhan, Canyang Yuan, Tianming Chen, Xiangxiang Ni, Yanyan Shen, Ying Chen, Weiwei Wu, Tai Yu, Huimin Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
title | Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
title_full | Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
title_fullStr | Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
title_full_unstemmed | Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
title_short | Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
title_sort | intravenous immunoglobulin g in the treatment of abo hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225508/ https://www.ncbi.nlm.nih.gov/pubmed/33589732 http://dx.doi.org/10.1038/s41372-021-00963-5 |
work_keys_str_mv | AT panjiarong intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT zhancanyang intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT yuantianming intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT chenxiangxiang intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT niyanyan intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT shenying intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT chenweiwei intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT wutai intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy AT yuhuimin intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy |